Skip to main content
BC Innovations
Feature Story

Home is in the placenta

How tumor-targeting peptides could de-risk drug development in pregnancy

By Lauren Martz, Senior Writer

Many drug developers have avoided stepping into what they see as the high risk area of pregnancy-associated complications, leaving diseases such as preeclampsia and fetal growth restriction with little innovation and few treatment options. By taking advantage of biological similarities between solid tumors and the placenta, a group from the University of Manchester has developed a drug delivery technology that could shift the risk-reward balance and spur companies to reopen the book.

In a paper published in Science Advances last month, the group, headed by Lynda Harris, a lecturer in pharmaceutics at the university, reported that two peptides known to target solid tumors also home to the surface of the placenta. Drug-loaded liposomes decorated with either peptide accumulated in the outer layers of the placenta without crossing into fetal circulation or accumulating in maternal organs.

Read Article

Today's Biotech & Pharma News

  • THE DISTILLERY brings you this week's most essential scientific findings in therapeutics, distilled by Innovations editors from a weekly review of more than 400 papers in 41 of the highest-impact journals in the fields of biotechnology, the life sciences and chemistry. The Distillery goes beyond the abstracts to explain the commercial relevance of featured research, including licensing status and companies working in the field, where applicable.

    This week in therapeutics includes important research findings on targets and compounds, grouped first by disease class and then alphabetically by indication.

    This week in techniques includes findings about research tools, disease models and manufacturing processes that have the potential to enable or improve all stages of drug discovery and development.

Subscribe Now
Free Trial